GXIPC1 is an allogeneic adipose-derived stem cells therapy for the treatment of diabetes. In pre-clinical research, GXIPC1 showed therapeutic potential in regulating blood sugar and protecting islets. Currently, GXIPC1 is executed in clinical trial I at Vinmec Research Institute of Stem Cell and Gene Technology (VIRISG) in Vietnam.

The phase I trial (NCT05308836) has been approved by the Ministry of Health of Vietnam (MOH) in Vietnam and initiated patient enrollment. Moreover, it is worth to point out that we are the first firm delivering qualified stem cell medicine overseas in Taiwan.